controls (0.074 AE 4.18, P = 0.845), and at 12 months (0.695 AE 2.97, P = 0.009, vs. 0.141 AE 5.05, P = 0.760). The differences in mean change in ACT scores between groups were not significant at 6 (P = 0.202) and 12 months (P = 0.296). There were non-significant reductions in exacerbations (ED visits: P = 0.312, Hospitalization: P = 0.121, OCS use: P = 0.099). No patients in the intervention group were rated as having 'poor' inhaler technique after appropriate counselling.
Methods: Medically confirmed HDM-AR pediatric participants were randomized to receive either 300IR HDM tablet or placebo once daily for 52 weeks. The primary endpoint was the average Adjusted Symptom Score ([ASS] a rhinitis symptom score adjusted for rescue medication use) of 300IR versus placebo (mixed model for repeated measures) during the final 4 weeks of treatment. Main secondary clinical endpoints were average ASS at Weeks 8-10, 16-18, 24-26, 32-34 and 40-42 , average Combined Score, average Rhinitis Total Symptom Score, Individual Rhinitis Scores, and general improvement assessed by the investigator. Safety was evaluated through reporting of adverse events (AEs).
Results: 438 patients (219 in active and placebo groups) were randomized. The ASS least-squares mean during the last 4 weeks was significantly reduced in the 300IR group versus placebo (relative difference: -13.1%). All secondary endpoints were also lower in the 300IR group. The most common treatment-related AEs (≥10%) reported in the 300IR group were application-site reactions: oral pruritus, mouth oedema, throat irritation, ear pruritus, and mouth swelling. One drug-related serious AE in the 300IR group (subglottic laryngitis on Day 22, 11 hours after drug intake) was resolved with inhaled adrenaline and corticosteroids. No deaths, intensive care unit admissions, or use of parenteral adrenaline were reported.
Conclusions: Treatment with 300IR HDM tablets was effective and clinically meaningful for patients aged 5-16 years. The safety profile observed in this age class was consistent with that observed in adults and adolescents. Methods: Subjects with medically confirmed HDM-AR were from double-blind placebo-controlled trials: Trial-1 in adults (18-50 years; Europe), Trial-2 in adults/adolescents (12-64 years; Japan), Trial-3 (5-17 years; Europe) and Trial-4 (5-16 years; Japan) both in children/adolescents. Participants were randomized to receive HDM tablets (300IR or 500IR in Trials 1, 2; 300IR in Trials 3, 4) or placebo once daily for one year. Immunological effect was assessed through HDM-specific serum IgE and IgG 4 assays before and after treatment (descriptive analysis). Adverse events (AEs) were reported for safety evaluation.
Results: The 4 trials comprised 2,386 subjects. Of these, 952 subjects received the 300IR tablet (Trial-1 = 170, Trial-2 = 322, Trial-3=241, Trial-4 = 219). During the treatment period of all trials, HDM-specific IgE increased (<2-fold) in the 300IR groups and remained stable in the placebo groups. HDM-specific IgG 4 was at least 2-fold higher in the 300IR groups with little change in the placebo groups. In the Trial-1 posttreatment year, IgE and IgG 4 remained higher than placebo in the 300IR group. In the 4 trials, the most commonly reported treatment-related AEs were application-site reactions e.g., oral pruritus, throat irritation. Three serious AEs were considered related to the 300IR tablet: pharyngeal oedema and eczema which resolved with antihistamines/corticosteroids in Trial-1 and subglottic laryngitis which resolved with inhaled adrenaline and corticosteroids in Trial-4. No deaths, intensive care unit admissions, or use of parenteral adrenaline were reported.
Conclusions: Data from 2,386 HDM-AR subjects from four Phase III trials indicate that HDM sublingual tablets are immunologically active and remained so over the Trial-1 post-treatment year. A similar safety profile was observed in adults, adolescents, and children.
P35 CONFIDENCE OF HOSPITAL TRAINEES IN THE DIAGNOSIS AND MANAGEMENT OF ANAPHYLAXIS
Claire Reynolds, Logan Denny, Shahad Al-Badri and Simon O'Connor Barwon Health, Geelong, Victoria, Australia Introduction: We aimed to assess the levels of confidence in our trainee cohort in the diagnosis and management of acute anaphylaxis, and what intervention would help to improve on this area.
Methods:
We invited hospital trainees from intern level to fellowship to participate in a 20-question survey. They were contacted via e-mail by our Medical Manpower Department. Data was collected and analysed using 'Research Electronic Data Capture (REDCap)' software.
Results: In total 102 trainees completed the survey. The majority were from Medicine, then Emergency Medicine. 57 (55.8%) were Post Graduate Year (PGY) 4 or above and 16 (15.4 %) were PGY 1. Regarding experience, 24 (23.3%) had no experience with acute anaphylaxis, and 18 (17.5%) had experience in 6 or more cases. 66 (64.7%) reported their confidence levels at 5/7 or higher for both diagnosing and managing anaphylaxis, with clinical experience noted as the main reason. This was cited over formal teaching as the reason for a lack of confidence also. Approximately one third of trainees identified causative allergens in >50% of cases, with 25% identifying it in 50% of anaphylaxis cases. While 57.7% reported educating on allergen avoidance after every case, the remaining trainees cited unknown trigger or insufficient time as barriers. 54% and 64% of trainees have never discussed adrenaline autoinjector use or discussed an Allergy Action Plan with patients, respectively.
Conclusion:
While we acknowledge bias in our cohort, with Medicine and Emergency Medicine making the majority, the group majority felt confident in the diagnosis and management of anaphylaxis. Formal university education is not as effective as clinical practice for building confidence, which may be facilitated by simulation teaching sessions, as shown in previous studies, to improve trainee performance in anaphylaxis management. 
